A New Approach To Prostate Cancer Detection
- Dr. Tom Rogers
- 5 hours ago
- 4 min read
Welcome to another edition of the Doctor's Note where we talk about what's on our minds when it comes to your health.
This week I had the privilege of sitting down with Dr. Garrett Pohlman, a renowned urologist from Nebraska and host of The Prostate Health Podcast, to talk about the changing landscape of prostate cancer screening. For years, we’ve wrestled with the limitations of the PSA (prostate-specific antigen) test. While it’s an essential tool, it’s far from perfect. In my four decades of practice, few areas have created as much uncertainty for clinicians and patients as the decision-making around elevated PSA levels. Is it inflammation, benign enlargement, infection, or is it cancer? It can be difficult to know, and the anxiety this uncertainty creates can be overwhelming. These challenges are why I’m so excited to discuss the EpiSwitch PSE test—a new advancement that’s showing remarkable accuracy in differentiating between high and low likelihoods of prostate cancer.
Dr. Pohlman explained how the EpiSwitch PSE combines five distinct epigenetic biomarkers with the PSA score to greatly increase diagnostic precision. Unlike older biomarkers such as IsoPSA or the 4Kscore, which can be ambiguous and difficult for patients to interpret, EpiSwitch PSE delivers a clear, binary result: high or low risk. This clarity empowers men to have productive conversations about next steps, whether that means further imaging, biopsy, or continued observation. Not only has this test improved clinical decision-making, but it has also helped reduce unnecessary biopsies and ease patient anxiety through clearer communication and individualized plans based on more accurate results. The technology is a real game-changer in the ongoing mission to detect prostate cancer early, when it’s most treatable, while also avoiding overtreatment of non-threatening cases.
PODCAST NOTES
The PSA test, while long considered the gold standard for prostate screening, is often problematic because it lacks the ability to distinguish between benign and malignant conditions within the prostate. As a result, elevated PSA can be caused by inflammation, infection, benign prostatic hyperplasia, or actual cancer, which leaves both patients and physicians uncertain about how to proceed, leading to confusion and often unnecessary further tests and procedures.
As Dr. Pohlman highlighted, only about 25% of men with an elevated PSA who undergo a biopsy are ultimately found to have prostate cancer. This means up to 75% are subjected to the anxiety and potential complications of biopsy without a cancer diagnosis, making it clear that better methods to identify who truly needs further investigation are urgently needed.
The introduction of the EpiSwitch PSE test represents a significant advancement because it combines five unique epigenetic biomarkers with the patient's PSA score. This innovative approach yields a diagnostic accuracy of about 94%, compared to about 25% accuracy with PSA alone—raising the bar for prostate cancer detection and supporting smarter clinical decision-making.
Unlike previous biomarker tests (such as IsoPSA and 4Kscore) that produced risk percentages or scores that were challenging for most patients to interpret, the EpiSwitch PSE test offers a straightforward, binary result: either a high or low likelihood of prostate cancer. This makes it much simpler for patients to understand their risks and decide on the next steps in their care.
With its role as a powerful triage tool, the EpiSwitch PSE test enables practitioners to better personalize subsequent care. For those at high risk, advanced imaging like MRI or a biopsy can be pursued; for those at low risk, ongoing surveillance may be sufficient. This strategy improves resource utilization and patient experiences by minimizing unnecessary interventions.
The enhanced accuracy and clarity provided by the EpiSwitch PSE have a direct positive impact on reducing unnecessary biopsies and treatments. By identifying those truly at risk, this test helps spare many men from the emotional and physical toll associated with invasive procedures and the uncertainty of ambiguous results, while also helping them feel more secure in their health decisions.
Importantly, EpiSwitch PSE is not intended to replace existing tools like PSA testing, MRI, or biopsy outright. Instead, it is best seen as a complementary resource that fills important gaps in current protocols, providing much-needed clarity and confidence for both patients and clinicians as they navigate complex decisions about prostate cancer risk.
Early detection of prostate cancer remains absolutely crucial, as survival rates are nearly 100% when the disease is caught before it spreads outside the prostate. The advancements discussed, including EpiSwitch PSE and newer imaging technologies, are playing a major part in shifting prostate cancer screening toward smarter, more individualized strategies that maximize benefit and minimize harm.
It’s clear that the EpiSwitch PSE test offers a major leap forward for men’s health and prostate cancer screening. It’s these types of innovations that give us transformative tools to detect cancers early and avoid unnecessary procedures for those who don’t need them. My conversation with Dr. Pohlman reminded me again just how rapidly our field is evolving and how important it is to stay informed.
If you or a loved one are navigating questions around prostate health, I strongly encourage you to talk with your healthcare provider about the best screening approach—and consider the EpiSwitch PSE as part of that discussion. And don’t forget to check out the Prostate Health Podcast and the resources in the Prostate Health Academy for more expert guidance.
Stay educated. Stay healthy.
Till next week.
